How to Know If Your Drug and Supply Costs Are Running Above Market
Drug and supply costs rise above market in independent physician-owned facilities without producing a clear indication in the facility’s own reporting. The movement happens inside the distributor relationship over months and years, in price increments too small for any individual invoice to warrant a formal review. By the time a physician-owner suspects something is wrong, the gap between what the facility pays and what the market bears has typically been building for two or three years. The question is not whether it is happening. What matters is what would have to be true for you to know.
Why Your Current Reporting Cannot Surface the Problem
Your P&L compares your drug and supply costs against your own prior periods. It flags variance relative to your own history. However, it has no mechanism to compare what you pay against what comparable independent facilities pay for the same inputs. According to VMG Health’s benchmarking data, the average ASC spends 26.3% of its operating budget on drugs and medical supplies — making it the second largest cost category after staffing. A facility paying 20% above market rates on contrast agents will see nothing unusual in its reporting if those rates increased gradually over three years. Every period looks close to the last one. The cumulative distance from market never appears as a named line item.
Your distributor contract compounds this. The contract establishes pricing terms and then auto-renews. Repricing within those terms happens on the distributor’s cycle, not yours. Each adjustment is defensible within the contract language. Your approval is not required. No notification is triggered. The cost rises. Your reporting tracks it faithfully. Neither document tells you whether the number reflects what the market actually bears for an independent facility at your volume and specialty mix.
This is the structural gap that makes above-market drug and supply costs invisible from inside most independent ASCs and OBLs. The visibility problem is not a function of how carefully the facility is managed. It is a function of what the facility’s reporting infrastructure was built to measure.
Three Indications That Costs May Be Running Above Market
Several operational patterns suggest drug and supply costs may have moved above market, even when reporting does not confirm it. None constitute proof. Each warrants a closer look.
The first indication is per-case margin compression that persists despite stable volume and reimbursement. When revenue holds and margin still falls, the pressure is coming from cost. If the cost increase is not attributable to a named change in clinical protocol, staffing, or device pricing, the commodity supply base is the most likely source. As examined in prior work on what margin erosion looks like in a physician-owned ASC, this pattern is the diagnostic signature of structural cost pressure rather than an episodic cost event.
The second indication is a distributor relationship in place for two or more years without a formal pricing review against peer facilities. Not a review of whether you are purchasing on contract. A review of whether your contract pricing reflects what comparable independent facilities at your volume and procedure mix are actually paying. These are different questions. Most independent facilities have answered the first. They have never asked the second.
The third indication is an operational fix that produced less margin improvement than expected. When you renegotiated a device contract and per-case margin did not move as predicted, something was absorbing the gain. Drug and supply costs running above market rates are the most common explanation. They absorb operational improvements without producing a clear indication of where the pressure originates.
What Confirming the Problem Actually Requires
The indications above suggest a problem. They do not quantify it. Confirming whether drug and supply costs have moved above market requires one specific input that does not exist inside your own operation: actual pricing data from comparable independent facilities purchasing the same or equivalent SKUs at similar volume and procedure mix.
Furthermore, that comparison is not available in published industry benchmarks. Those aggregate across facility types too broadly to be useful at the line-item level. Your distributor cannot provide it. And your GPO will not provide it either — it confirms that you are purchasing on contract but does not compare your rates against what comparable independent facilities negotiate independently.
The comparison requires access to invoice-level pricing from peer independent facilities. That data exists. However, it has not historically been on the independent operator’s side of the table. Facilities that have seen it have mapped their own purchase history against peer pricing at the SKU level. They have consistently found gaps that were invisible anywhere in their prior reporting.
If you want to know whether your drug and supply costs are running above market, request your complimentary supply cost analysis at vantumpartners.com. Your purchase data compared against documented peer pricing. You see the number. No obligation.
Frequently Asked Questions
How do I know if my drug and supply costs are above market for my ASC or OBL?
The clearest indication is per-case margin compression that persists despite stable volume and reimbursement, particularly when operational interventions produce less improvement than expected. However, the only way to confirm whether drug and supply costs are running above market is a direct comparison of your actual invoice-level pricing against what comparable independent facilities pay for the same inputs at equivalent volume and specialty mix. That comparison does not exist inside your facility’s own reporting. It requires external peer pricing data your internal infrastructure was not built to hold.
Why do drug and supply costs rise above market without appearing in financial reporting?
Drug and supply costs rise above market through incremental repricing inside the distributor relationship on a contract renewal cycle. Each adjustment is small enough to avoid triggering a formal review. The cumulative movement across multiple SKUs over 24 to 36 months creates a material gap between what the facility pays and what the market bears. However, because the movement distributes across many line items in small amounts, standard financial reporting never produces a named variance that identifies it as the source of cost pressure.
Does my GPO contract protect my ASC or OBL from drug and supply costs running above market?
A GPO contract establishes a pricing floor and confirms that purchases are made on contract. However, it does not actively monitor whether your contract pricing reflects market rates for comparable independent facilities at your current volume and procedure mix. Drug and supply costs can move above market inside a GPO relationship when contract terms auto-renew without a formal comparison against what peer facilities negotiate independently. The GPO confirms contract compliance. It does not confirm market competitiveness.
How long do above-market drug and supply costs typically go undetected in an independent facility?
Above-market drug and supply costs typically go undetected for as long as the distributor relationship has been in place without a formal external benchmark comparison. For most independent physician-owned ASCs and OBLs, that means the above-market costs have been accumulating since the original contract was established. Without a mechanism inside their financial reporting to compare costs against what peer facilities pay, there is no internal trigger that would surface the gap. It remains invisible until an external comparison is run against actual peer pricing data.
What is the difference between a contract pricing review and a market benchmark comparison?
A contract pricing review confirms that your facility purchases at the rates specified in your distributor agreement. In contrast, a market benchmark comparison determines whether those contracted rates reflect what comparable independent facilities at your volume and specialty mix actually pay for the same inputs. Most independent facilities have conducted the first and never asked the second. The contract review tells you whether you are paying what you agreed to pay. Separately, the benchmark comparison tells you whether what you agreed to pay reflects the market.